Search Results
Your search for can matches 13497 pages
Showing 8951 - 9000Combination of Nivolumab and Ipilimumab Moves Forward in NSCLC
How best to combine new immunotherapies is a burning question in oncology. A new study in the CheckMate series suggests that nivolumab (Opdivo) and ipilimumab (Yervoy) can be safely and effectively combined as first-line treatment of advanced non–small cell lung cancer (NSCLC),1 but further study...
Approximately 20% of Older Women With Early Breast Cancer Experience Some Form of Functional Decline After Treatment
In a study of older women with newly diagnosed stage I to III breast cancer, approximately 1 in 5 lost the ability to complete some of the basic tasks necessary for independent living within 1 year of initiating treatment. The study also found that a simple survey can help identify which women are...
Primary Care Visits Result in More Colorectal Cancer Screening, Better Follow-up
People who visit their primary care physicians are more likely to get potentially life-saving colon cancer screenings and follow-up on abnormal stool blood test results—even in health systems that heavily promote mail-in home stool blood tests that don’t require a doctor visit, a study...
Women With High-Grade Cervical Intraepithelial Neoplasia Have Long-Term Increased Risk for HPV-Related Anal, Vulvar, and Vaginal Cancers
Although high-risk human papillomavirus (HPV) is essential for developing high-grade cervical intraepithelial neoplasia (CIN2 and CIN3) and has also been associated with noncervical anogenital cancers, little is known about the long-term risk for anal, vulvar, and vaginal cancer following a...
Richard Pazdur, MD, Named Acting Director of the FDA Oncology Center of Excellence
U.S. Food and Drug Administration (FDA) Commissioner Robert Califf, MD, issued the following statement today regarding the appointment of the Acting Director of the FDA Oncology Center of Excellence. “The FDA is honored to be an integral part of the Vice President’s National Cancer...
FDA Approves Sofosbuvir/Velpatasvir for Treatment of Chronic Hepatitis C Virus Infection
On June 28, the U.S. Food and Drug Administration (FDA) approved a fixed-dose combination of sofosbuvir, 400 mg, plus velpatasvir, 100 mg (Epclusa) to treat adult patients with chronic hepatitis C virus (HCV) either with or without cirrhosis. For patients with moderate to severe cirrhosis...
ASCO Outlines Opposition to Medicare Part B Demo for Senate Finance Hearing
ASCO voiced its strong opposition to the proposed Medicare Part B demonstration project in comments submitted on June 28 for the U.S. Senate Finance Committee hearing, “Examining the Proposed Medicare Part B Drug Demonstration.” ASCO underscored the urgent need to advance a fairer...
CAP, IASLC, and AMP Seek Public Comments on Revised Lung Cancer Molecular Testing Guideline
The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) announced today the open comment period for the revised evidence-based guideline, “Molecular Testing Guideline for Selection of...
Influence of Microbiota of Breast Tissue on the Development of Cancers
Bacteria that have the potential to abet breast cancer are present in the breasts of cancer patients, while beneficial bacteria are more abundant in healthy breasts, where they may actually be protecting women from cancer, according to Gregor Reid, PhD, of the Lawson Health Research Institute, and...
Lawrence O. Gostin, JD, LLD, Appointed to National Cancer Advisory Board
President Barack Obama has tapped Lawrence O. Gostin, JD, LLD, Georgetown University Professor and Faculty Director of the O’Neill Institute for National and Global Health Law at Georgetown Law, to serve as a member of the National Cancer Advisory Board (NCAB). He will serve a 6-year term. The 18 ...
Precision Medicine Clinical Trial for Metastatic Pancreatic Cancer Now Open at Multiple Sites
The first clinical trial to compare standard-of-care chemotherapy with molecularly tailored therapy (also known as precision medicine) for metastatic pancreatic cancer is now enrolling patients at multiple sites around the country. Patients who have been treated with one round of chemotherapy for...
Use Questions From Patients to Help Them Make Informed Treatment Decisions
Recent reports about treatment options for patients with ductal carcinoma in situ, and the ensuing debate and comments played out in the media, may prompt increased questions from patients. A review summarizing data about these treatment options concluded that surgery and radiation therapy “remain...
Surgery and Radiation Therapy Remain Standard of Care for Managing Ductal Carcinoma in Situ
A review of more than 50 studies (many randomized controlled trials) concluded that surgery and radiation therapy “remain standard-of-care treatment options” in the management of ductal carcinoma in situ.1 The review continues the widely reported discussion on managing ductal carcinoma in situ,...
Taubman Prize Jointly Awarded to Suzanne L. Topalian, MD, and Jedd D. Wolchok, MD, PhD, for Groundbreaking Work in Cancer Immunotherapy
Two clinician-scientists whose groundbreaking work has shown how the human body’s own immune system can fend off cancer will share the 2016 $100,000 Taubman Prize for Excellence in Translational Medical Science, the University of Michigan’s A. Alfred Taubman Medical Research Institute announced....
Something Happened
Over the years, my patients have been my most important teachers. I’ve learned so much from them about human nature and the resilience of the human spirit. When my time came to pass through the fire and confront the same challenges they and their families face so bravely and with such compassion, ...
Inside Knowledge From a Cancer Survivor
Curtis Pesmen is a well-regarded writer who has authored six books of nonfiction as well as numerous articles for publications such as Esquire and The New York Times. He also has served as founding editor of LIVESTRONG Quarterly and often speaks and writes on patient advocacy. Shortly after...
St. Jude Children’s Research Hospital Names Michael Dyer, PhD, Chair of Developmental Neurobiology
St. Jude Children’s Research Hospital has named Michael Dyer, PhD, Chair of the Department of Developmental Neurobiology. “A true visionary in his field, Dr. Dyer is a remarkable scientist who has worked tirelessly to unravel some of the long-held mysteries of childhood cancer,” said James R....
Moonshot Program for … Compassion
A 65-year-old patient with widely metastatic pancreatic cancer was emergently transferred to our facility in the early hours of the morning with free air suggestive of a perforated viscus. The patient is from a small town several hundred miles away from our academic center, which can be quite...
Katherine L. Nathanson, MD, Receives AACR’s Frohlich Visiting Professorship
Katherine L. Nathanson, MD, Professor of Medicine in the Division of Translational Medicine and Human Genetics at the Perelman School of Medicine of the University of Pennsylvania, has received the 2015 Frohlich Visiting Professorship through the American Association for Cancer Research (AACR)....
Vanguard Practices Support Sharing Big Data With CancerLinQ™
CancerLinQ LLC, recently announced that it has completed agreements with 36 vanguard oncology practices from around the country to begin implementing the tool. According to physicians at the vanguard practices, gaining access to the experience of oncology practices across the country motivated...
Meet Thomas G. Roberts, Jr, MD
Thomas G. Roberts, Jr, MD, is Managing Member at Farallon Capital Management, LLC and Chair of the Conquer Cancer Foundation of ASCO Board of Directors and Executive Committee. What led you to oncology prior to your career in finance? TGR: As an intern at Massachusetts General Hospital, I was...
Expanded Content on Geriatric Oncology
Cancer.Net has newly updated information specifically for older patients with cancer and is expanding coverage of this segment of cancer care across the site. Direct your patients and their caregivers to cancer.net/olderadults to find articles on aging and cancer, making treatment decisions, and...
Clinical Conversations: Attendee Questions From the Cancer Survivorship Symposium
The inaugural Cancer Survivorship Symposium, held in January 2016, drew more than 800 attendees across the cancer-care spectrum—far exceeding the goal of 500 attendees. As a way to continue the discussion from the meeting, several faculty members responded to questions from General Sessions 5 and...
ASCO Endows Young Investigator Award in Honor of Society Founder Jane Cooke Wright, MD
For the first time in ASCO’s history, the Society has endowed its own Young Investigator Award (YIA), illustrating its continued commitment to investing in the future of cancer research. Ongoing support of this kind will ensure that the Conquer Cancer Foundation (CCF), ASCO’s philanthropic arm, is...
Geriatric Patients With Cancer and the Problem of Polypharmacy
Older patients with cancer generally have multiple comorbidities, with each often requiring separate medications. Studies have shown that polypharmacy and inappropriate drug use are prevalent among older cancer patients, leading to an enormous amount of preventable adverse events, many requiring...
Anti–PD-1 Treatment With Pembrolizumab in Gastric/Gastroesophageal Junction Cancers: Who Is Likely to Respond?
Immune checkpoint inhibitors have emerged as one of the most promising new areas of drug development in oncology. Broad activity has been observed for these agents across a spectrum of hematologic malignancies and solid tumors. As reviewed in this issue of The ASCO Post, Muro and colleagues now...
Nivolumab or Ipilimumab Treatment May Increase Risk of Developing Autoimmune Joint and Tissue Disease
Case reports on 13 patients with cancer suggest that patients taking the immunotherapeutics ipilimumab (Yervoy) and nivolumab (Opdivo) may be at higher-than-normal risk of developing autoimmune joint and tissue diseases, including inflammatory arthritis, according to a preliminary study by Johns...
Tackling the Symptoms of Long-Term Fatigue and Insomnia in Cancer Survivors
Fatigue and sleep disruption are common occurrences for most patients diagnosed with cancer. Simply having a serious physical illness like cancer along with its associated pain, hospitalization, and treatment, as well as the attendant psychological impact, all contribute to the onset of fatigue...
A Conquer Cancer Foundation Award Helps to Launch a Pioneering Study in Liposarcoma
Mark A. Dickson, MD, has been fascinated by science and medicine since he was in high school. After graduating magna cum laude from Harvard University in 1999, Dr. Dickson pursued a medical degree from the College of Physicians and Surgeons at Columbia University in New York. Once he decided on a...
Cervical Cancer Prevention Badly Needed in India
With the advent of the Papanicolaou (Pap) test and population-based screening, along with the development of the human papillomavirus (HPV) vaccine, cervical cancer has become a largely preventable disease for many. However, in India, cervical cancer is a leading cause of cancer mortality. To...
Ixazomib: A Relevant Addition to Myeloma Therapy
In 2015, four new drugs were approved for the treatment of multiple myeloma by the U.S. Food and Drug Administration: panobinostat (Farydak), daratumumab (Darzalex), elotuzumab (Empliciti), and ixazomib (Ninlaro). Of them, the first three are drugs with unique new targets, whereas ixazomib is the...
Medical Decision-Making: At the Heart of Care for Older Patients With Cancer
Although oncology has moved toward a personalized approach to care, medical decision-making within the context of multidisciplinary care has broad public health implications. To shed light on this and other relevant issues, The ASCO Post recently spoke with William Dale, MD, PhD, of the University ...
Creating Hybrid Academic-Community Cancer Centers to Improve Patient Care
Five years ago, the Helen F. Graham Cancer Center and Research Institute at Christiana Care Health System in Newark, Delaware, and The Wistar Institute, a National Cancer Institute (NCI)-designated biomedical research center, in Philadelphia, Pennsylvania, joined forces to collaborate on...
Updated WHO Classification of Hematologic Malignancies
Question 1: Which statement about the classification of tumors of hematopoietic and lymphoid tissues is true? Correct Answer: A. The revised WHO classification defines distant disease entities that can be reliably diagnosed using proposed criteria. Expert Perspective WHO last updated its...
Updated WHO Classification of Hematologic Malignancies
WHO last updated its classification of tumors of hematopoietic and lymphoid tissues with a fourth edition of its WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, in 2008, as part of a series of WHO Classification of Tumours monographs. This year, with the support of the...
Treatment Update in Gastric, Pancreatic, and Colorectal Cancers
Although new gastrointestinal cancers are on the rise, advancements in their treatment, as well as the upcoming results of perioperative trials, could prove to be “clinical practice game-changers,” declared Thomas J. George, Jr, MD, FACP, at the 2016 Community Oncology Conference in Orlando,...
Expert Point of View: Samir Gupta, MD
Samir Gupta, MD, Associate Professor of Medicine at the University of California San Diego, who has led trials of colorectal cancer screening, commented on this study for The ASCO Post. Although there are approximately 138,000 new colorectal cancer diagnoses a year in the United States, only...
Expert Point of View: Peter C. Enzinger, MD
Not so FAST? The study discussant Peter C. Enzinger, MD, Director of the Center for Esophageal and Gastric Cancer at Dana-Farber/Brigham and Women’s Cancer Center, Boston, viewed the findings of the FAST trial as promising but voiced several considerations, as did Gulam A. Manji, MD, PhD,...
Matching Treatment to Tumor Abnormalities Seems to Pay Off
A strategy of matching molecular abnormalities in patients’ tumors to therapies targeted to those abnormalities is gaining ground, according to preliminary results of the phase IIb MyPathway study presented at the 2016 ASCO Annual Meeting.1 These are still early days for this “matching” strategy,...
CAR T-Cell Therapy Using Double Target Aimed at Solid Tumors in Preclinical Models
Chimeric antigen receptors (CARs), engineered from a patient's own immune cells, have been successful for treating blood cancers, but using CARs for solid tumors has been limited by side effects to normal tissues containing the protein targeted by the engineered cells. Now, in a report published...
Expert Point of View: Don Dizon, MD
Don Dizon, MD, Chair of ASCO’s Cancer Communications Committee, congratulated the authors of the OV21/PETROC study. “This is another example of international collaboration. The authors looked at the role of IP therapy in women who got primary chemotherapy before surgery, and at least in this...
Expert Point of View: Sumanta K. Pal, MD, and Richard Schilsky, MD
Sumanta K. Pal, MD, an ASCO spokesperson who moderated a press briefing at the 2016 ASCO Annual Meeting, commented that the data provide key insights into the feasibility of “liquid biopsy.” “We’re increasingly using genomic data from day to day in our clinics to guide therapies,” said Dr. Pal....
‘Liquid Biopsy’ Stacks Up Well to Tissue Biopsy in Detecting Tumor-Specific Mutations
So-called liquid biopsy identified cancer mutations in 85% of all advanced tumors, in the largest-ever evaluation of circulating tumor DNA (ctDNA) in the blood.1 In 49% of the cases, these biomarkers were associated with an approved targeted drug, Philip C. Mack, PhD, reported at the 2016 ASCO...
Supporting Policy to Reduce Tobacco-Related Deaths
One billion lives. That is the estimated human death toll of tobacco use in the 21st century.1 Tobacco use is the leading cause of preventable death worldwide—20% of all deaths and 30% of cancer deaths in the United States are linked to tobacco use.2,3 Impacting this preventable public health...
ASCO Releases the Updated Version of Its Value Framework
Last June, ASCO published its initial concept for a value framework in the Journal of Clinical Oncology (JCO).1 The framework, developed by ASCO’s Value in Cancer Care Task Force, is designed to provide a standardized approach to assist physicians and patients in assessing the “value” of a new...
Autologous Stem Cell Transplantation Offers Safe, Effective Option for Patients With HIV-Associated Lymphoma
A phase II, multicenter trial published by Alvarnas et al in Blood challenges the generally held belief that individuals with human immunodeficiency virus (HIV) and aggressive lymphoma are not candidates for standard treatment. According to the researchers, people with HIV-associated lymphoma who...
Patient Navigators Improve Comprehensive Cancer Center Screening Rates
A clinical trial conducted by Massachusetts General Hospital (MGH) investigators has found that the use of patient navigators—individuals who assist patients in receiving health care services—may improve comprehensive cancer screening rates among patient populations not likely to...
Report Finds Families of Cancer Survivors Challenged by Intense, Episodic Caregiving Experiences
A new report shows that people caring for a loved one with cancer often have more intense, episodic caregiver responsibilities than those caring for someone with other health needs. The report, from the National Alliance for Caregiving in partnership with the National Cancer Institute and the...
SNMMI 2016: VASH Collimator Allows Three-Dimensional Imaging of the Breast With Less Radiation
Preliminary tests have demonstrated that a new device may enable existing breast cancer imagers to provide up to six times better contrast of tumors in the breast, while maintaining the same or better image quality and halving the radiation dose to patients. The advance is made possible by a new...
Protein Could Help Identify Chronic Graft-vs-Host Disease
A new study published by Kariminia et al in the journal Blood has identified a protein that could diagnose chronic graft-vs-host disease in patients undergoing blood and bone marrow transplantation. The work was led by researchers in the Michael Cuccione Childhood Cancer Research Program at BC...
